Bromocriptine mesylate-loaded nanoparticles co-modified with low molecular weight protamine and lactoferrin for enhanced nose-to-brain delivery in Parkinson’s disease treatment

[Display omitted] •BCM was successfully incorporated in LMWP and Lf co-modified nanoparticles.•LMWP/Lf-BCM-NPs had narrow polydispersity, favourable stability, and semi-spherical shape.•LMWP/Lf-BCM-NPs had the transport ability in vitro cell model, with good biocompatibility.•LMWP/Lf-BCM-NPs (i.n.)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of pharmaceutics 2025-01, Vol.669, p.125054, Article 125054
Hauptverfasser:	Cong, Huijing, Hu, Jing, Wang, Jing, Chang, Baiyu, Li, Rongtao, Cui, Xinran, Zhang, Chenghao, Ji, Hongyu, Lin, Congcong, Tang, Jingling, Liu, Jiaxin
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intranasal Animals Antiparkinson Agents - administration & dosage Antiparkinson Agents - chemistry Antiparkinson Agents - pharmacokinetics Brain - drug effects Brain - metabolism Bromocriptine - administration & dosage Bromocriptine - pharmacokinetics Co-modified nanoparticles Disease Models, Animal Drug Carriers - chemistry Drug Delivery Systems Haloperidol - administration & dosage Haloperidol - pharmacokinetics Humans Lactoferrin Lactoferrin - administration & dosage Lactoferrin - chemistry Low molecular weight protamine Male Mice Molecular Weight Nanoparticles - administration & dosage Nanoparticles - chemistry Neuroprotective Agents - administration & dosage Neuroprotective Agents - chemistry Neuroprotective Agents - pharmacokinetics Nose-to-brain delivery Parkinson Disease - drug therapy Parkinson’s disease Polylactic Acid-Polyglycolic Acid Copolymer - chemistry Protamines - administration & dosage Protamines - chemistry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!